Phase I Study of Alternate‐Day Administration of S‐1, Oral Leucovorin, and Bevacizumab for Refractory Metastatic Colorectal Cancer

LESSONS LEARNED: The recommended S‐1 dose was 40 mg/m(2), twice daily on Monday, Wednesday, Friday, and Sunday, with oral leucovorin and bevacizumab. Compared with daily administration, the alternate‐day administration of S‐1 with oral leucovorin may reduce mucositis with promising antitumor activit...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Masuishi, Toshiki, Taniguchi, Hiroya, Komori, Azusa, Mitani, Seiichiro, Narita, Yukiya, Kadowaki, Shigenori, Ura, Takashi, Ando, Masashi, Muro, Kei
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons, Inc. 2020
Témata:
Clinical Trial Results
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7648368/
https://ncbi.nlm.nih.gov/pubmed/32490554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0463
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky